Effects of esketamine and lidocaine on pain and survival after liver surgery
Official title: Effect of Perioperative Continuous Intravenous Infusion of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy
Run by West China Hospital · NCT06778460 · Data updated 2026-11-12
This study is testing if a combination of esketamine and lidocaine can help reduce pain and improve survival for people having liver surgery for cancer compared to standard pain relief methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 304 (estimated) |
| Sponsor | West China Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | May 5, 2023 |
| Main results expected | March 31, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | January 16, 2025 |
| Trial ID | NCT06778460 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 scheduled for elective hepatectomy with ASA grades I-III.
✕Probably not a fit
Patients with severe cardiac or hepatic insufficiencies, or those with a history of long-term opioid abuse may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the long-term effects of esketamine and lidocaine on postoperative chronic pain, quality of life, and survival rates in patients undergoing hepatectomy for primary liver cancer. A total of 304 patients will be randomly assigned to receive either the esketamine-lidocaine treatment or a conventional analgesia regimen. The treatment group will receive a continuous infusion of esketamine and lidocaine during and after surgery, while the control group will receive a placebo. Pain levels will be assessed using a numeric rating scale at various postoperative intervals, and follow-up will track chronic pain and survival outcomes over five years.
Why it matters
Potential benefit: If successful, this approach could significantly reduce chronic pain and improve long-term survival for patients undergoing liver surgery.
How similar studies have gone: Other studies have shown promising results with similar analgesic approaches, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged 18-75 years; 2. Scheduled for elective hepatectomy; 3. ASA grade I-III. Exclusion Criteria: 1. Patients who have been intubated in the ICU following surgery and do not have a planned extubation within 6 hours postoperatively. 2. Patients with a body weight less than 40 kg or greater than 100 kg. 3. Patients with cardiac conduction system abnormalities (second- or third-degree atrioventricular block) or cardiac insufficiency (left ventricular ejection fraction \< 50%). 4. Patients with severe hepatic insufficiency (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or bilirubin levels more than 2.5 times the upper limit of normal) or renal insufficiency (creatinine clearance rate \< 60 mL/min). 5. Patients with a known hypersensitivity to the investigational drug. 6. Patients with a history of long-term opioid abuse. 7. Patients who are unable to communicate effectively. 8. Patients with serious comorbid medical conditions, such as uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, or acute asthma exacerbations. 9. Patients with a history of epilepsy or a history of manic episodes. 10. Pregnant or breastfeeding women. 11. Patients with glaucoma. 12. Patients with preoperative cognitive dysfunction, bipolar disorder, or other psychiatric disorders, including mental retardation. 13. Patients with primary liver cancer in conjunction with malignant tumors of other organs (such as lung, kidney, intestine, etc.), or those with clinical symptoms or imaging findings suggestive of distant metastasis.
Where it's running
-
West China Hospital
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: Chunling Jiang, PhD
- Email: jiang_chunling@yahoo.com
- Phone: 18980601096
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Two Ways to Help Pain After Breast Surgery: Education-Based Analgesia vs Standard Care
This trial tests whether teaching patients about pain management and using a multimodal pain plan improves pain control and recovery after breast surgery compared with standard care.
-
Chronic Postoperative Pain after Cardiac Surgery: Incidence and Impact
This survey checks how often people have chronic pain 3 months after cardiac surgery and who it affects most, to see if the rate is lower than 33%.
-
Buprenorphine via PCA vs oxycodone for pain after VATS
This trial tests whether intravenous buprenorphine given through a patient-controlled pump provides better and safer pain relief than intravenous oxycodone after video-assisted thoracic surgery in adults.
-
IV pain medicine, thoracic epidural, and erector spinae plane block for long-term pain after open-heart surgery
This study will compare three common pain-control approaches—IV pain medicines, thoracic epidural, and erector spinae plane block—to see if one lowers chronic pain three months after open-heart surgery.
-
Evaluating the effectiveness of spinal cord stimulation for chronic pain relief
This study is testing if spinal cord stimulation can help people with chronic leg pain after back surgery feel better compared to a placebo treatment.
-
Effects of early mobilization on recovery after obesity surgery
This study tests if getting up and moving around soon after obesity surgery helps patients recover faster and feel less pain.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.